Search Results
Jun 02, 2026, 09:30 ET Early Data Show Highly Selective FGFR2 Inhibitor 3HP-2827 Active in Advanced CCA; Chinese Academy of Sciences' Zhou Jian Comments on Potential for Patients With FGFR2 Alterations
FGFR2 mutations occur across a wide range of solid tumors — including biliary tract cancers, gynecologic malignancies, melanoma, colorectal cancer, lung cancer, gastric cancer and urothelial carcinoma — representing a patient population larger than that of FGFR2 fusions or rearrangements. The longstanding
More news about: 3H Pharmaceuticals
Jun 02, 2026, 09:05 ET Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
investigational thromboxane A2 receptor antagonist, in patients with solid tumors at high risk of early metastatic recurrence. Cancer types included breast, lung, pancreatic, soft tissue, bladder, and renal cancers.The study met its primary endpoint, demonstrating that ifetroban was safe and well-tolerated
More news about: Cumberland Pharmaceuticals Inc.
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
allogeneic invariant natural killer T (iNKT) cell therapies. Its lead candidate, agenT-797, recently moved into a randomized Phase 2 trial in severe acute lung injury, with preliminary data expected in the second half of 2026, and its cancer work has shown durable activity signals in solid tumors. MiNK reported
More news about: USA News Group
Jun 02, 2026, 08:57 ET Penn Highlands Healthcare Expands Allied Health & Nursing Workforce Pipeline Through Scholars Network Program Offering Up to $65,000 in Loan Repayment
and support talent," said Heather Franci, MBHA, BSN, RN, Chief Nursing Officer and Service Line Director for Penn Highlands Healthcare's Heart Center, Lung Center, Brain & Spine and Oncology Services. "Through this approach, we're able to connect with future clinicians earlier, reduce financial barriers,
More news about: Scholars Network
Jun 02, 2026, 08:48 ET Florida Cancer Specialists & Research Institute Welcomes Medical Oncologist and Hematologist Elke K. Friedman, MD to Stuart Cancer Center
Board-certified physician brings extensive experience in breast, lung and hematologic malignancies, clinical research and patient-centered cancer care to Martin County.FORT MYERS, Fla., June 2, 2026 /PRNewswire/
More news about: Florida Cancer Specialists & Research Institute
Jun 02, 2026, 08:42 ET JOMS Study: Botox Injection May Help Reduce Pain and Opioid Use After Corrective Jaw Surgery
MyOMS.org.The authors of "Effect of Preoperative Botulinum Toxin A on Pain and Opioid Consumption After Bilateral Sagittal Split Osteotomy" are Kevin E. Lung, DDS, MD, MSc, BSc,; Jason Adam, DDS, BSc,; Clayton Davis, DDS, MD, MSc; Matthew Fay, DDS, MD, MSc; and Daanesh Zakai, BDS (Wales) MRCS RCS Ed, MBChB.The
More news about: AAOMS/Journal of Oral and Maxillofacial Surgery
Jun 02, 2026, 08:30 ET IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Jun 02, 2026, 07:00 ET Altesa BioSciences Appoints Brett Haumann, MBBCh, MBA, to its Board of Directors and Gwen Skloot, MD, ATSF, as Senior Vice President for Clinical Development
utilization, and lung function.About Altesa BioSciences, Inc.Altesa BioSciences is a clinical-stage pharmaceutical company, led by global experts in respiratory medicine and infectious diseases. We are dedicated to improving the lives of people with chronic lung diseases, like
More news about: Altesa Biosciences Inc.
Jun 02, 2026, 07:00 ET Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
More news about: Evogene
Jun 02, 2026, 04:39 ET ANUA CHỌN KENDALL JENNER LÀ ĐẠI SỨ THƯƠNG HIỆU TOÀN CẦU ĐẦU TIÊN
da căng bóng lung linh. Tôi cực kỳ hâm mộ các sản phẩm này," Kendall Jenner nói.PDRN Collagen Glow Facial Serum Spray, sản phẩm xịt dạng viên nang với 2.000ppm PDRN (ADN cá hồi) và Axit Hyaluronic. Sản phẩm xịt này cấp ẩm tức thì và mang lại lớp nền lung linh, mịn màng
More news about: Anua
Jun 01, 2026, 18:16 ET /C O R R E C T I O N -- Ranok Therapeutics/
Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026, issued 01-Jun-2026 by Ranok Therapeutics over PR Newswire, we are advised by the company that the first sub-headline,
More news about: Ranok Therapeutics
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243.International Agency
More news about: Amgen
Jun 01, 2026, 09:00 ET Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Jun 01, 2026, 08:31 ET The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
market.LAS VEGAS, June 1, 2026 /PRNewswire/ -- Non-small cell lung cancer is increasingly evolving into a biomarker-driven market, with EGFR-mutated disease emerging as one of the most commercially significant segments.
More news about: DelveInsight Business Research, LLP
Jun 01, 2026, 08:11 ET Cancer Vaccine Sustains 49 Percent Melanoma Reduction After 5 Years
firstline therapy in combination with pembrolizumab for melanoma. Already, the vaccine is being tested to see if it also works to prevent recurrence of lung and other cancers. For the KEYNOTE-942 trial, patients were enrolled at cancer centers in Australia and the United States from 2019 to 2021.
More news about: NYU Langone Health System
Jun 01, 2026, 08:00 ET SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
SystImmune, Inc., a clinical-stage biotechnology company, today announced the oral presentation of Phase 1 data for BL-M14D1 in patients with small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors (BL-M14D1-101, NCT06505824) at the American Society of Clinical Oncology (ASCO)
More news about: SystImmune, Inc.
Jun 01, 2026, 08:00 ET Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
clinical trial of NBE-002, a first-in-class immune-stimulatory antibody-drug conjugate targeting ROR1 in triple-negative breast cancer, non-small cell lung cancer, and sarcoma. NBE-Therapeutics was subsequently acquired by Boehringer Ingelheim for $1.4 billion. Before NBE, Dr. Heeger was CMO of Selvita
More news about: Actinium Pharmaceuticals, Inc.
Jun 01, 2026, 08:00 ET GIGABYTE ra mắt dòng bo mạch chủ AORUS INFINITY X870E và X870 nhân kỷ niệm 40 năm tại COMPUTEX 2026
mới, chỉ có thể chế tạo thông qua công nghệ in kim loại 3D, giúp tăng diện tích bề mặt làm mát lên đến 44%. Khi kết hợp cùng buồng hơi in 3D và tấm ốp lưng kim loại cấu trúc tổ ong, giải pháp này giúp đẩy kỹ thuật tản nhiệt của bo mạch chủ cao cấp vượt qua mọi giới hạn truyền thống. Sản phẩm cũng được trang
More news about: GIGABYTE
Jun 01, 2026, 07:00 ET Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3
More news about: Actinium Pharmaceuticals, Inc.
Jun 01, 2026, 03:51 ET Cipla Health touches 1500+ lives through multi-city on-ground screening and awareness initiatives on World No Tobacco Day
Cipla Health partnered with leading medical and dental institutions and associations to conduct screening camps that combine oral health check-ups with lung health assessments. The initiative aims to enable individuals to undergo early screenings and, where required, be guided towards further diagnosis and
More news about: Cipla Health
Jun 01, 2026, 01:51 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
the ASCO Annual Meeting. This year, the company's research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class
More news about: Hengrui Pharma
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
indications. The program has received three Breakthrough Therapy Designations and is currently being evaluated in two Phase 3 studies in second-line small cell lung cancer (SCLC) and second-line esophageal squamous cell carcinoma (ESCC).Minghui is advancing additional clinical development strategies for MHB088C.
More news about: Minghui Pharmaceutical
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
could ultimately offer transformative treatment options for patients with lung cancer, colorectal cancer, and a broad range of solid tumors."Key Highlights of the Poster Presentations：Non-Small Cell Lung Cancer (NSCLC)In the ongoing Phase I/II study, CS2009 was
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the treatment of advanced immunotherapy(IO)-resistant non-small cell lung cancer (NSCLC) The detailed data was presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.The updated data
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) plus chemotherapy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). The detailed data was presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.This study is the
More news about: Innovent Biologics